<DOC>
	<DOC>NCT03055403</DOC>
	<brief_summary>This Phase I first-in-human is designed to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of M201-A administered by single continuous intravenous injection in Healthy Japanese subjects.</brief_summary>
	<brief_title>First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects</brief_title>
	<detailed_description>Not Provided</detailed_description>
	<criteria>Subjects must satisfy the following criteria to be enrolled in the study: Japanese Healthy Male subjects Age 20 to less than 40 years of age Body Mass Index (BMI) of 18.5 to less than 25.0 kg/m2 Written informed consent must be obtained on a voluntary basis before any assessment is performed. The presence of any of the following will exclude a subject from enrollment: Presence or past medical history of hepatic impairments, renal impairments, cardiovascular disease, gastrointestinal disease and others which are inappropriate for participating in this clinical trial Past medical history of cancer, cerebral infarction or cardiac infarction Presence or past medical history of allergic reactions or idiosyncrasies to food, medicinal substance and metallic materials QTcF &gt; 450ms at the screening examination NTproBNP &gt; 125 pg/mL at the screening examination Any risk factors of Torsades de Pointes including such as heart failure, hypokalemia, long QT interval syndrome due to family medical history</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>